Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.97 USD | -0.05% | +0.72% | -30.45% |
May. 07 | MoonLake Immunotherapeutics Q1 Net Loss Widens | MT |
May. 07 | MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.45% | 2.64B | |
+17.21% | 121B | |
+13.71% | 107B | |
-5.85% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.45% | 15.31B | |
+3.17% | 14.08B | |
+23.84% | 11.74B |
- Stock Market
- Equities
- MLTX Stock
- News MoonLake Immunotherapeutics
- Barclays Adjusts Price Target on MoonLake Immunotherapeutics to $41 From $28, Keeps Equalweight Rating